Kanawati

RANITIDIN KANAWATI 300 mg

Capsules

Antiulcer drugs

Chemical Composition
Ranitidine (HCL) 300 mg
Packing
30Capsules
Medical Id
CA-10
License Number
157/2012
License date
29/3/2012

Mechanism Of Action	Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2-receptors, including receptors on the gastric cells. It .inhibits the gastric acid secretions, and also reduces pepsin secretion
INDICATIONS	Ranitidine Kanawati capsules are used to treat ulcers of the stomach and intestines and prevent them from returning after treatment. This medication is also used to treat and prevent certain stomach and throat (esophagus) problems caused by too much stomach acid (e.g., Zollinger-Ellison syndrome, erosive esophagitis) or a backward flow of stomach acid into the esophagus (gastroesophageal reflux disease-GERD). Ranitidine helps heal and prevent ulcers and improves symptoms such as heartburn and stomach pain.
CONTRAINDICATIONS	Ranitidine Kanawati is contraindicated in patients known to have hypersensitivity to ranitidine or any other components of the product.
Side EFFECTS	Some rare adverse effects of ranitidine may occur, such as skin hypersensitivity reactions, headache, nausea, dizziness, constipation or diarrhea, and tiredness
WARNINGS	Ranitidine Kanawati should be used with caution in patients with a history of acute porphyria. Since ranitidine is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function. Caution should be observed in patients with hepatic dysfunction since ranitidine is metabolized in the liver. Symptomatic response to therapy with ranitidine does not preclude the presence of gastric malignancy. Pregnancy (Category B) Teratogenic Effect: This drug should be used during pregnancy only if clearly needed. Nursing Mothers: Ranitidine is secreted in human milk. Caution should be exercised when ranitidine is administered to a nursing mother.
DRUG INTERACTIONS	Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes. Procainamide: High doses of ranitidine have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Warfarin: There have been reports of altered prothrombin time among patients on concomitant warfarin and ranitidine therapy. Close monitoring of increased or decreased prothrombin time is recommended. Ranitidine may alter the absorption of some drugs such as : Atazanavir: Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH. Use with caution. Delavirdine: Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H2-receptor antagonists with delavirdine is not recommended. Gefitinib: Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium bicarbonate. Use with caution. Glipizide: In diabetic patients, glipizide exposure was increased by 34% following a single 150-mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine. Ketoconazole: Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was coadministered in a regimen to maintain a gastric pH of 6 or above. Midazolam & Triazolam: Monitor patients for excessive or prolonged sedation when ranitidine is coadministered with oral midazolam or triazolam. Because of increasing exposure.
Storage Conditions	Store between15° - 30° C. Keep out of the reach of children. Store away from the light and moisture